Why the study?
Does a permutation method evaluating multiple clinical endpoints identify efficacious therapies and enable dose selection in acute heart failure proof-of-concept studies?
Does a permutation method evaluating multiple clinical endpoints identify efficacious therapies and enable dose selection in acute heart failure proof-of-concept studies?
A permutation method evaluating multiple clinical endpoints in proof-of-concept studies can help identify efficacious therapies and optimal doses while accounting for correlated endpoints.
Answers are grounded in this paper and cite their sources.
May aid multi-endpoint analysis and dose selection in acute HF PoC studies; leaves open prospective validation before wider use.
BACKGROUND: Clinically relevant endpoints cannot be routinely targeted with reasonable power in a small study. Hence, proof-of-concept studies are often powered to a primary surrogate endpoint. However, in acute heart failure (AHF) effects on surrogates have not translated into clinical benefit in confirmatory studies. Although observing an effect on one of many endpoints due to chance is likely, observing concurrent positive trends across several outcomes by chance is usually unlikely. METHODS: Pre-RELAX-AHF, which compared 4 relaxin doses with placebo in AHF, has shown favourable trends versus placebo (one-sided P < 0.10) on six of nine clinical endpoints in the 30 μg/kg/day group. To illustrate evaluation of multiple, correlated clinical endpoints for evidence of efficacy and for dose selection, a permutation method was applied retrospectively. By randomly re-assigning the treatment group to the actual data for each of the 229 subjects, 20,000 permutation samples were constructed. RESULTS: The permutation P value for at least six favourable trends among nine endpoints in any dose groups was 0.0073 (99.9% CI 0.0053-0.0093). This is higher than would be expected if the endpoints were uncorrelated (0.00026), but much lower than the probability of observing one of nine comparisons significant at the traditional two-sided P < 0.05 (0.74). Thus, the result was unlikely due to correlated endpoints or to chance. CONCLUSIONS: Examining consistency of effect across multiple clinical endpoints in a proof-of-concept study may identify efficacious therapies and enable dose selection for confirmatory trials. The merit of the approach described requires confirmation through prospective application in designing future studies.
No takes yet. Share an insight, caveat, or question.
Davison et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: